KRaSCENDO Trial. Excellent results comparing Divarasib (anext generation KRAS inhibitor) with sotorasib showing a clear benefit in PFS, OS, with rapid and durable responses. @on

Manuel Dómine, MD, PhD· @ManuelDomine · X·2026-10-25 23:50· 1 天前评分70

正文 · 原文

KRaSCENDO Trial. Excellent results comparing Divarasib (anext generation KRAS inhibitor) with sotorasib showing a clear benefit in PFS, OS, with rapid and durable responses. @oncoalert @myesmo #ESMO2026 MADRID @Hospital_FJD @quironsalud #LCSM

29 浏览 · 4 赞 · 2 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Manuel Dómine, MD, PhD · x.com